• Around 40% of available marketed drugs are poorly bioavailable or soluble, and about 90% of New Chemical Entities are known for their low solubility and permeability
• Lexaria’s patented DehydraTECH(TM) technology offers a solution by improving how APIs (active pharmaceutical ingredients) enter the bloodstream
• DehydraTECH achieves this by bypassing first-pass-liver metabolism
• By doing so, Lexaria is facilitating faster and much more thorough drug delivery

In a report published in the Bioavailability Enhancement Technologies and Services Market, 2018-2030, it was established that around 40% of available marketed drugs are poorly bioavailable or soluble. It was further estimated that approximately 90% of New Chemical Entities (“NCEs”) belong to Biopharmaceutics Classification System (“BCS”) class II and IV, known for their low solubility and permeability (https://ibn.fm/xfrBh). Today, a significant number of drugs fail to reach the market owing to their poor bioavailability. This has prompted companies to re-formulate existing product candidates and explore different tools and methods to try to solve the problem. Lexaria Bioscience (NASDAQ: LEXX) has taken on the challenge and is currently leading the industry in terms of innovation in drug delivery platforms. Its patented DehydraTECH(TM) technology is specifically designed to improve how active pharmaceutical ingredients (“APIs”) enter the bloodstream, ultimately increasing the effectiveness of fat-soluble molecules. Lexaria’s DehydraTECH is a product of years of research and millions of dollars in investments. So far, the technology is covered by 23 issued and over 50 pending patents in 40 different countries worldwide. The demand for solutions is so acute, that more and more companies are offering technologies and/or services geared towards bioavailability enhancement. In addition, several players have even developed novel, industry-leading technologies to maintain a competitive edge in this market that is showing great potential for growth. Lexaria recognized this opportunity back in 2014 and has been investing aggressively into research and the strategic partnerships it has forged so far. Bioavailability can be described as how much an APIcan access the bloodstream within the body. This is typically dependent on absorption as well as secretion. It works on the principle that an API can only offer benefits if it can be absorbed into the body in the first place (https://ibn.fm/8DNGH). One way through which drugs, particularly orally administered ones, have their bioavailability compromised is through first-pass liver processing. Usually, once they are ingested, they must travel from the intestine to the liver for metabolization, before they are circulated within the body and eventually to their targeted area. This arduous process can reduce the amount of drug that actually reaches the bloodstream by as much as twenty-fold inhibiting the effectiveness of the drug itself. Because DehydraTECH bypasses this first-pass liver processing, the drugs begin to reach the bloodstream in as little as two minutes and often reach blood concentration levels between 100% and 200% higher. In addition, given the effectiveness of this technology, patients can also enjoy reduced drug dosing which has the potential to significantly lower the cost of treatment. Lexaria remains committed to exploring new ways through which its DehydraTECH technology can help even more people. So far, it is investigating new products for hypertension, anti-viral treatments, oral nicotine, and other drug classes, with notable progress made so far. The company is also conducting research and development on several critical indications, including epilepsy, dementia, rheumatoid disease, diabetes, human hormones, Ibuprofen and Naproxen (“NSAIDs”), and PDE5 inhibitors. Lexaria understands the value and usefulness of its technology, hence its commitment to further research and partnering with other strategic players within the industry. Its efforts improve the bioavailability of pharmaceuticals and therapeutics, one drug class at a time. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• The artist with the highest number of tickets sold in December will win a $500 cash prize
• Artists will be able to keep 100 percent of revenue from ticket sales
• Additional winning opportunities are available for artists who promote at least three events on Instagram
• A comprehensive guide to setting up ticketed streams is available for artists on the Fan Pass website

Mobile technology and marketing company Friendable (OTC: FDBL) is continuing the tradition of its monthly contest with generous prizes and other revenue-earning opportunities for members of the Fan Pass Live artist platform. For the month of December, the company will reward artists who sell the highest number of tickets via ticketed streaming events organized on the platform. The artist who sells the most tickets will receive a cash prize of $500. The second prize is worth $250, and the third prize is worth $150. An additional $30 bonus is available to artists who will promote three of their ticketed events on Instagram and tag the Fan Pass platform (@fanpasslive) on their posts. Artists will be able to organize and host their ticketed events on Fan Pass completely free of charge and will get to keep 100 percent of their ticket sales. Everyone interested in participating can access a detailed guide to setting up ticketed streaming events on the Fan Pass website (https://ibn.fm/tV3HG). Monthly artist contests are just one of the multiple revenue-generating opportunities artists can leverage on the Fan Pass platform. The revenue structure available for artists who sign up for Fan Pass can help members generate income by selling tickets to private events, selling merchandise, taking part in monthly contests, content views, and more. Since its launch in July 2020, Fan Pass has seen massive growth, with thousands of artist sign-ups in the last 12 months, including both established and independent artists. This year, the platform has reached multiple significant milestones, including the launch of an updated version, the publication of new mobile applications in both the Apple Store and Google Play, and the release of an Artist Pro offering that brings new features and benefits for members, for a monthly subscription of $8.99. Artists who sign up for the Artist Pro option are able to access an advanced dashboard, valuable analytics and marketing services, while also being able to sell custom merchandise and promote scheduled musical events. Fans who subscribe to the platform have the opportunity to gain exclusive access to the artists, allowing them to see their daily lives and get exclusive engagement opportunities, all covered by a highly affordable monthly fee. After the launch of Fan Pass v2.0, the company started monetizing an “ALL ACCESS VIP” offering for fans, available for a monthly subscription of $2.99 or an annual subscription of $25.99. The company goes into 2022 with a commitment to continue expanding its reach and offering to artists and fans alike. According to CEO Robert Rositano Jr., one of the opportunities the company is considering involves artists being included on playlists through partnerships with celebrities, but no specific details are yet available (https://ibn.fm/S1kxg). The company also intends to work toward making Fan Pass a household name, with hundreds of thousands of artists launching their careers and earning revenue via the platform, while also focusing on going global to reach a worldwide audience of artists and fans alike. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

Date: December 15–17, 2021 Venue: Moscone Center San Francisco, 747 Howard St, San Francisco, CA 94103 NCIA’s 7th Annual Cannabis Business Summit & Expo is the premiere national destination for everyone interested in the legal cannabis sector. Join like-minded professionals December 15-17, 2021 at the Moscone Center in San Francisco — the gateway to the Emerald Triangle — to brush up on the latest trends, explore new products and services, and tap into the support of a national network. Also known as #CannaBizSummit, this event is the ideal opportunity to re-energize your business and career. Hosted by the National Cannabis Industry Association (“NCIA”), the largest and oldest national trade association advancing the interests of the cannabis industry, Cannabis Business Summit & Expo is the industry’s most influential national B2B trade show. Gathering over 125 speakers, more than 80 educational sessions, and hundreds of brands, #CannaBizSummit is the only event that brings together an exclusive lineup of education, exhibitors, and experiences under one roof. Furthermore, through networking mixers and after parties, event guests from throughout the country, including licensed merchants, cultivators, cannabis sector business owners, and consumer enthusiasts, will have the opportunity to form significant connections with fellow professionals. Key points to remember:

• Hundreds of exhibitors will showcase the latest technology, goods, and services. Visitors will be able to shop and compare benefits side by side, plus watch live demos.
• Expert industry speakers will reveal tricks of the trade and key insights to help individuals future-proof their cannabis business, even in the face of economic and environmental change.
• Attendees can enjoy the networking mixer, after parties, and gain one-on-one time with suppliers throughout the show, as opportunities to reconnect with colleagues and forge new business relationships.
• Attend educational sessions covering a range of topics across the entire cannabis ecosystem. On the new Live Podcast Stage, people may also watch live recordings of their favorite podcasts.
• The new BLOOM: A Brands Experience gives an exciting opportunity to explore cannabis products from brands all over the country.
• Attend off-site excursions to see how other dispensaries and operations deliver excellent products and services to their customers.

NCIA’s 7th Annual Cannabis Business Summit & Expo will feature the premiere of BLOOM, a “show within a show” that will provide attendees with a unique sensory experience, allowing them to view, touch, and smell items from dozens of brands specializing in flower, vapor, pre-roll, oils, edibles, and more. These vendors will be featured in a custom-designed, easy-to-navigate neighborhood setting. Retailers, infused product manufacturers, distributors, and cultivators with Cultivators with an active state license may attend the Expo, Keynote Sessions, and General Sessions on a complimentary basis. Additional ticketing options start at $59. For more information, please visit https://ibn.fm/ZUMXO

• 2021 marked Mydecine’s patent application for its MYCO-003 drug candidate
• It also marked notable clinical trials on various aspects, including smoking cessation
• Mydecine also got into a 5-year research agreement with JHU for clinical research on the use of psychedelics for therapeutics
• These milestones have laid down the groundwork, not just for Q3 of the 2021 financial year but also for the company’s growth in the 2022 calendar year

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), since its inception in 2020, has been aiming to transform the treatment of mental health disorders and addiction through biotechnology. The company has already developed first and second-generation novel therapeutics geared towards treating addiction, post-traumatic stress disorder (“PTSD”), and other mental health disorders. Mydecine recently released its third-quarter 2021 update and a noteworthy announcement for the 2021 calendar year. It offers a glimpse into achievements to date, and what stakeholders can anticipate in the last quarter of the 2021 financial year and for the 2022 calendar year (https://ibn.fm/OnAyi). Most notably, Mydecine filed a patent application for its MYCO-003 drug candidate to treat PTSD and anxiety. It also filed a new patent for MDMA-like compounds, as well as a technology patent for the creation of formulations that use nano-emulsion technologies to enhance, stabilize and make repeatable properties of ingredients from traditional medicine. These and other patent applications are helping to expand Mydecine’s robust portfolio of novel compounds while also increasing value to shareholders. Going into the last quarter of the 2021 fiscal year, Mydecine is proud to commence with its 5-year research agreement with John Hopkins University (“JHU”) School of Medicine for clinical research related to the use of psychedelics for therapeutics. The company is also excited to proceed with MYCO-001, one of its lead candidates, through Phase 2/3 clinical trials for smoking cessation. It is projected that by 2026, the smoking cessation market will be valued at $63.99 billion, representing a CAGR of 16.9% over the forecast period- 2018-2026 (https://ibn.fm/AJSJJ). On the other hand, the psychedelic therapeutics market is estimated to be valued at $6.5 billion by 2030, representing a CAGR of 15% over the forecast period- 2018-2030. With the growing popularity and interest in psychedelic therapeutic drugs, Mydecine has recognized an opportunity in this segment. This is evidenced by its investment in clinical trials and its advancements with its technologies. From the groundwork laid down over the 2021 calendar year, it is projected that 2022 will be a big year for Mydecine, and offers hope to those suffering from mental health and addiction disorders. For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• PLGNF adds three iGaming operators to platform, additional eight at testing and integration stages
• Growth indicators from November include 12% player wager increase, 28% active player growth, 22% increase in bet spots
• PLGNF’s proprietary technology enables seamless integration at operator level, allows user access without sharing sensitive data or requiring app store download.
• PLGNF has a typical SaaS business model which includes zero player acquisition cost.
• Grandview Research forecasts global online gambling market to reach $127.3 billion by 2027, CAGR of 11.5% from 2020 to 2027

Playgon Games (TSX.V: DEAL) (OTCQB: PLGNF), a propriety SaaS technology company delivering live dealer mobile technology to global online gaming operators, recently announced the addition of three new operators to its platform, bringing the total to 26. The company also reported that critical key performance indicators were up for November, including 12% growth in player wagering, a 28% increase in monthly active player numbers, and 22% growth in bet spots (https://ibn.fm/iw6zA). “We continue to garner strong interest and onboard operators rapidly as the demand for our product continues to grow at a healthy pace,” said Darcy Krogh, CEO of Playgon Games. “Player activity and wagering are important metrics of the success of our mobile live dealer product, and we are delighted with the growth we are experiencing. For the second month in a row, we are delivering record increases in player wagering, which is a direct function of the growing number of users leveraging our platform as we offer our games through some of the largest gaming operators globally.” PLGNF’s iGaming software provides a multi-tenant gateway that allows global online operators to deliver an authentic casino experience streamed live from Las Vegas. Games include Live Dealer Casino, E-Table Games and Daily Fantasy Sports. Their Live Casino is presented with high-definition live streaming dealers and state-of-the-art augmented reality technology that gives users a best-in-class user experience without sharing sensitive data or requiring an app store download. The company expects the growth trend to continue driven by 4 key pillars, the pandemic, new regulation, technology, and user demographic. “As we look ahead to the new year, we anticipate continued growth in client acquisition and player activity with a material number of new operators coming online and ultimately strong revenue growth,” said Krogh. “We are confident in our strategy and look forward to continued growth and success.” Krogh was recently featured on the Investor Brand Network’s Bell2Bell podcast, where he revealed details about the company’s successful growth strategy in addition to insights into the massive expansion being seen in the iGaming sector (https://ibn.fm/7BVYU). “We’re 80 strong with employees, including 20 engineers, with our core product being live dealer table games. We have 60 dealers in our studio in Las Vegas who deliver the content to our customers. We are a growing, publicly-traded, Malta-licensed, mobile-focused development company in a high growth industry.” Grandview Research forecasts the global online gambling market to reach $127.3 billion by 2027, at a CAGR of 11.5% from 2020 to 2027 (https://ibn.fm/BQw4G). Factors such as innovations in artificial intelligence and machine learning, increased options for digital payments, and an expanding female segment are all expected to contribute to market growth. PLGNF is positioned favorably with its portfolio of IP-protected assets, high barriers to entry, and decades of management experience with multiple successful exits. For more information, visit the company’s website at www.Playgon.com. NOTE TO INVESTORS: The latest news and updates relating to PLGNF are available in the company’s newsroom at https://ibn.fm/PLGNF

• Canadian-based clean energy solutions innovator FuelPositive Corp. is focused on developing green ammonia as a more efficient and sustainable source of fuel than the popular fossil fuel alternative hydrogen
• FuelPositive’s Hydrogen-Ammonia Synthesizer technology provides the means of storing hydrogen as green ammonia for effective transportation and storage, with the option of easy conversion back to hydrogen for use in hydrogen fuel cells and other pure hydrogen applications
• The company is among a handful of entities that have noted Canada’s outsized support for fossil fuels recently, and plans to roll out its IP next year in “real world” demonstration pilot projects
• Carbon footprint reduction has gained global attention in recent years amid concerns about climate change resulting from pollutants, and policy representatives from around the world recently gathered in Scotland for the COP26 2021 United Nations Climate Change Conference to address related issues

When green energy innovator FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) commissioned an analysis of Canada’s green off-peak electricity capacity earlier this year to help measure the fuel needs and carbon emissions of the country’s transportation sector, FuelPositive was adding its own insights to a recent series of examinations of Canada’s renewable energy performance. Oil Change International, which tracks public finance of fossil fuels, reported last month that Canadian fossil fuel producers receive more public financial support than any others in the developed world, and that Canadian renewable energy received far less in public financial support than many other countries provide to their industries (https://ibn.fm/434r3). The report noted that both the federal government and Export Development Canada — the agency that handles most of the financing — have pledged they’ll reduce fossil fuel financing during the coming years, with the Liberal party setting a deadline of 2023. Export Development Canada expects to reduce support to the six most carbon-intensive sectors by 40% below 2018 levels before the deadline, according to the report. FuelPositive is in the business of developing and commercializing green energy solutions and gaining standout technology innovation in the sector through partnerships and acquisition, specifically in regard to “green ammonia” produced in a carbon-free manner for use in a variety of applications that contribute to environmental sustainability at a time when climate change is a profound concern for world governments. FuelPositive’s patent-pending green ammonia (“NH3”) technology is an advanced Hydrogen-Ammonia Synthesizer, a highly portable and scalable and modular system the company plans to introduce next year in “real world” demonstration pilot projects as it advances toward commercial production (https://ibn.fm/QPvbF). Carbon-free green ammonia has the potential to become a fossil fuel alternative — the company notes that planes, trains, ships, trucks, and other vehicles can be converted to run on ammonia as easily as they can be converted to run on propane instead of gasoline or diesel. Additionally, FuelPositive’s Hydrogen-Ammonia Synthesizer technology can convert air, water, and sustainable electricity to store hydrogen in the form of green ammonia, allowing hydrogen to be more efficiently stored or transported than it would be in liquid hydrogen form which requires high-pressure tanks and cryogenic storage temperatures. An end user can then easily convert the green ammonia back into hydrogen for use in producing electricity in a hydrogen fuel cell when that is required by transportation vehicles, according to the company. FuelPositive is also pursuing the development of green ammonia fuel cells which are a new and attractive alternative to hydrogen fuel cells. Following the latest international climate summit, branded COP26, many researchers have described hydrogen as the best source for generating renewable energy (https://ibn.fm/SRSx5) because when hydrogen burns, the only by-product is water. But hydrogen has traditionally been generated from fossil fuels, which only compounds the challenges of developing clean energy goals. Former California Gov. Arnold Schwarzenegger was expected to attend the COP26 2021 United Nations Climate Change Conference talks, which concluded Nov. 12, and appeared in the news prior to the summit as part of a wide-ranging interview in which he criticized some of the excuses policy advisers use for resisting transition to sustainable fuel sources. “They are liars, they are stupid. Or they don’t know how to do it, because we figured how to do it (in California),” Schwarzenegger told the BBC (https://ibn.fm/iFNDp). Schwarzenegger has built his own brand on performance fitness celebrity over the past several decades and, more recently, on environmental sustainability goals. He told the interviewer he was particularly alarmed at pollutants that result from shipping and suggested shopping locally is the most important thing individuals can do to cut carbon emissions. “Buy local products. Every time you buy something from overseas, that is evil for the environment — this is like the worst thing you can do. … You can have (international) competition but you have to be smart about it … because if people are dead, they are dead. It’s over.” For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• Multiple ongoing studies are researching the relationship between medical cannabis and cancer treatment
• The viability of clinical studies within the sector is hampered by lack of exact measurement of a patient’s intake
• RYAH Group intends to resolve this issue with the launch of it’s proprietary RYAH Smart Dry Herb Inhaler
• The company successfully delivered on its first Inhaler order in May 2021, and announced that they had received a follow-on order in November 2021

In 1980, The United States National Cancer Institute (“NCI”) began experimental distribution of a novel drug called Marinol, an oral form of THC (the primary active ingredient in cannabis), to cancer patients in San Francisco (https://ibn.fm/HE5vn). Just over a decade later, the city of San Francisco celebrated the passing of Proposition P in 1991, a revolutionary bill that legalized the use of medical cannabis within the city limits. There’s an abundance of evidence supporting the use of medical cannabis to treat cancer symptoms. Now, rather than just treating symptoms, science has begun to ask, “could cannabis be used to treat cancer itself”? A recognized leader in volume management technology for plant-based medicine, RYAH Group (CSE: RYAH) is in the middle of the action. RYAH develops innovative IoT products that capture powerful data insights and is on a mission to to transform patient care using big data and AI to reshape understanding and uses of plant-based medicines. The company’s robust artificial intelligence platform aggregates and correlates HIPAA-compliant patient data, which then helps doctors and patients personalize plant-based treatments to better predict treatment outcomes. Little wonder that RYAH devices and data are being used by a rapidly growing number of participants in plant-based clinical trials around the world. While clinical research into the relationship between medical cannabis consumption and cancer treatment is in the very early stages, initial studies have shown that THC and other cannabinoids bind to the endocannabinoid receptors on cancer cells, thereby interrupting the cell’s ability to signal. With limited intracellular signals, the studies have witnessed increased cancer cell apoptosis, reduced proliferation, migration, and metastasis (https://ibn.fm/rSirx). Two key constraints that have limited the viability of cannabis studies within an oncological setting are the highly variable nature of the cannabis plant and traditional methods of cannabis consumption that make patient intake challenging to measure. The RYAH Group intends to resolve this issue with the launch of their proprietary RYAH Smart Dry Herb Inhaler. The product is the first dry-herb inhaler that tracks and controls how much is inhaled, providing consistent and predictable results. The inhaler connects with the RYAH Health App, which features stat-tracking and presets for temperatures and measurements, all of which can be customized to individual needs and doctor recommendations. Moreover, the device also permits a post-session review mechanism that collects session data, an essential requirement for any clinical study. In June 2021, the RYAH Group announced that it had completed its first shipment of RYAH Smart Dry Herb Inhalers, which included delivery of approximately 10,000 RYAH Cartridges and QR codes, to an international clinic undertaking one of the world’s largest and most comprehensive clinical trials in plant-based medicine (https://ibn.fm/XkFrG). In early November, the company announced that it had received a separate, follow-on order for its proprietary Inhaler product from the same company (https://ibn.fm/gALMy). While it is far too early for patients to forego traditional oncological treatments in favor of standalone medical cannabis therapy, clinical trials worldwide seek to discern the relationship between medical cannabis consumption and cancer treatment. While the trials currently lie at a relatively nascent stage, RYAH Group and its diverse and proprietary volume control and management device portfolio are playing their part in what may, one day, turn out to be a genuinely revolutionary medical breakthrough. For more information, visit the company’s website at www.RYAHGroup.com. NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH

• 1 in 8 adults are forecast to suffer from diabetes by 2024, with over 1 in 10 deaths in 2021 a direct result of the disease
• As many as 40% of Covid-19 related fatalities in the US also suffered from diabetes at the time of their passing
• Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices
• In addition to sugarBEAT, its flagship device, the company also recently announced the launch of MiBoKo, a combined application and non-invasive glucose sensor designed to help users track their metabolic scores

By 2024, the International Diabetes Federation (“IDF”) predicts that the number of people with diabetes is expected to rise to 1 in 8 adults. Nearly 7 million adults have died worldwide in 2021 so far due to diabetes or its related complications – astoundingly, accounting for over 1 in 10 global deaths from any cause. While enormous, that figure does not consider the lives lost to the novel coronavirus, which has shown to be particularly deadly for people with diabetes. A study found that having Type 1 or Type 2 diabetes tripled the risk of severe illness or death from COVID-19 (https://ibn.fm/laj37). “As many as 40% of the people that have died in the US from COVID-19 had diabetes,” said Dr. Robert Gabbay, chief scientific and medical officer for the American Diabetes Association. Founded in 2011, Nemaura Medical (NASDAQ: NMRD),  a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, set out to develop a single platform technology to measure blood markers at the surface of the skin. Since then, the company has evolved by creating wearable technologies and digital health care solutions that encourage and empower people to take charge of their health and well-being. The company’s flagship product, sugarBEAT(R), is a wearable, non-invasive and flexible Continuous Glucose Monitor (“CGM”) designed to help people with diabetes and prediabetes manage their glucose levels. The company has recently followed up with the release of the MiBoKo application. This service, which has been in development for the past 18 months, seeks to address a significant mass-market opportunity which the company believes could benefit roughly a third to half of the global population. The MiBoKo application uses a non-invasive glucose sensor to measure and monitor the user’s metabolic health scores, which are based on glucose tolerance or insulin resistance. Prediabetic patients, those facing obesity concerns, or individuals looking to monitor their glucose intake would all benefit from this application. A recent study carried out using anonymized health care data from a sample of over 16,000 people with both type 2 diabetes and COVID-19 found that people with type 2 diabetes who contracted Covid-19 were nearly 50% more likely to wind up in intensive care if they had mismanaged their blood sugar levels over the long-term, relative to those with better long-term glycaemic control (https://ibn.fm/8ySDC). With the COVID-19 virus rapidly gaining endemic status worldwide, diabetic and prediabetic patients are more at risk than ever before. By launching their unique and functional glucose monitoring devices, Nemaura Medical has sought to address this growing health risk, providing individuals afflicted with diabetes the world over with a more accessible, non-invasive method to monitor their health. For more information, visit the company websites at www.NemauraMedical.com. NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

• PlantX reported strong results for the three months ended September 30, 2021 (Q2 2022), with year-on-year increases in both gross revenue and gross profits
• Q2 2022 has seen PlantX roll out numerous initiatives designed to enhance its e-commerce impact, including launching as a third-party seller on Amazon Marketplace and Walmart Marketplace; opening new brick-and-mortar locations in California under its XMarket brand; and launching a meal delivery service
• The company also facilitated educational programming on plant-based lifestyles
• The accomplishments from these initiatives demonstrate PlantX’s increased effectiveness and commitment to its e-commerce expansion in line with its goal to add value to the plant-based industry

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), a company redefining the plant-based community through e-commerce initiatives, educational programs, and more, recently released its interim unaudited financials for the three and six months ended September 30, 2021, constituting Q2 and H1 2022 results (https://ibn.fm/B1wdW). Key Q2 2022 highlights from the November 29 announcement included a gross revenue of CA$2.8 million, representing a year-on-year increase of roughly CA$2.5 million from Q2 2021 figures. PlantX also recorded gross profits of $1.3 million in Q2 2022, an 8025% year-on-year growth compared to $15,913 recorded in Q2 2021. As of September 30, the company had working capital of $10.2 million, inclusive of cash of $9.6 million. In addition to the stellar year-on-year growth reported, Q2 2022 also saw the company make significant progress in diversification and implementation of new technology, the launch of physical retail stores, and facilitation of education programming on the plant-based lifestyle. PlantX launched as a third-party seller on Amazon Marketplace in both Canada and the United States as well as on Walmart Marketplace in the United States, further augmenting its e-commerce operations by leveraging Amazon’s and Walmart’s world-class e-commerce resources. The move is likely to help PlantX position itself as a leader in the plant-based space and increase its impact as it expands its in-house brands. The company also launched a meal delivery service, XFood, in Southern California with plans to later expand throughout the U.S. A collaborative effort between itself and celebrity chef Matthew Kenney, who is also PlantX’s partner at XMarket, XFood aims to reach as many people with plant-based options as possible. In addition, PlantX announced the launch of its redesigned Shopify-powered Canadian website. The refreshed site offers a modern design, upgraded functionality and search tools, and more straightforward navigation. Q2 2022 also saw PlantX implement novel initiatives that complement its e-commerce operations. For instance, the company launched new brick-and-mortar locations in San Diego, California, and Venice Beach, California, expanding the number of XMarket sites to three, with the third located in Squamish, British Columbia. At the same time, PlantX announced new physical locations opening up inside the Hudson Bay stores in Toronto and Ottawa (https://ibn.fm/EHDEh). Notably, PlantX’s XMarket brand represents the company’s redefined physical retail presence. The XMarket ecosystem, PlantX says, is focused on boosting brand awareness and customer engagement, improving plant-based education, creating new supply chain infrastructure, establishing a core consumer base, and driving sustainable e-commerce growth. “It has been an active quarter for PlantX as we continue to devote our efforts towards achieving our strategic expansion plan,” stated PlantX Founder Sean Dollinger. “From scaling our operational capabilities, to expanding our customer base and enhancing our educational pursuits, we have demonstrated increased effectiveness in line with our goal to add value and increase our impact in the fast-growing plant-based industry.” “As we approach the end of 2021, our focus is to support our community as best we can throughout the holiday season and advance our progress with creativity and passion,” Dollinger concluded. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

Fashion can be fun but make no mistake, it can be profitable too. The global apparel market is coming off a historic decline caused by lockdowns, social distancing, and economic slowdowns due to the COVID-19 outbreak and the measures to contain it. COVID still lingers but the apparel market looks ripe for rebound and ready to hit new highs. During the lockdown, consumers strayed away from purchasing new apparel. However, apparel companies still have the potential to deliver good earnings and significant capital gains. Not only is the industry huge, but it also ripe for rebound with much higher seasonal demand during the holidays. Time to shed the sweatpants, get dressed for success and get serious about some apparel. Some the largest, most popular apparel labels are owned and operated by unfamiliar names like PVH Corp. (NYSE: PVH) which has multiple brands under its umbrella including Van Heusen, Tommy Hilfiger, and Calvin Klein among others. Formerly known as the Phillips-Van Heusen Corporation, PVH also licenses brands such as Kenneth Cole New York and Michael Kors. PVH is one of the largest global apparel companies in the world reporting $7.1 billion in 2020 revenues. PVH reported third-quarter fiscal 2021 results, where the bottom line surpassed the Zacks Consensus Estimate, while the top line missed the same. However, both metrics improved year over year. The Calvin Klein segment improved 22% year over year and the Tommy Hilfiger segment rose 12%. A top hedge fund, Pzena Investment Management, had $439 million invested in the stock at the end of September and in a strong indicator, an insider purchased 1,981 shares at $81 in September 2020. The company also noted in the Q3 report that holiday season sales are off to a solid start and management raised the fiscal 2021 view. Another name not quickly recognized as an apparel behemoth is VF Corporation (NYSE: VFC). Their brands include Dickies, JanSport, Kipling, The North Face, Timberland, Vans, and Supreme. The company controls 55% of the US backpack market across all of its brands, making it a major player in the clothing industry. Across all their segments, the VF Corporation generated close to $10.5 billion U.S. dollars in global revenue in 2020 and the company ranked first based on revenue of leading apparel companies worldwide in 2019. The company reported improved results for Q2 fiscal 2022 last October. Overall revenue from continuing operations increased 23 percent. Outdoor segment revenue increased 31 percent, Work segment revenue increased 18 percent, International revenue increased 18 percent, and Direct-to-Consumer revenue increased 32 percent. Full year fiscal 2022 revenue is now expected to be approximately $12.0 billion, reflecting growth of around 30 percent. An intriguing apparel name, Digital Brands Group, Inc. (NASDAQ: DBGI) (www.digitalbrandsgroup.co) is redefining retail and the customer experience with its digital first, curated group of lifestyle brands. The company currently offers contemporary womenswear through Bailey 44 (www.bailey44.com), premium denim and luxury essentials through DSTLD (www.dstld.com), and luxury menswear through ACE Studios (www.acesuits.com). Digital Brands Group’s unique business model is capitalizing on increased global digitization and the long-time fragmentation of the apparel and fashion markets. The company operates its brands on a decentralized basis with separate executive teams running each brand while consolidating marketing and technology contracts and cross marketing to each brand’s customers. Since going public last May, the company has rapidly gained traction and increased leverage by rolling up brands and creating scale. Digital Brands reported impressive Q3 2021 results last November -third quarter 2021 net revenue increased 75% year over year and the gross profit margin increased 96% year over year to 55.9%. DBGI also provided eye-popping net revenue guidance for fiscal year 2022 – an increase of 350% from 2021 with 2022 revenue expectations of $37.5M to $42.5M. The company forecasts positive EBITDA for 2022 as it leverages its shared services platform.  Commenting on the surging growth, Hil Davis, CEO of Digital Brands Group, stated “This forecasted increase of 350% in our year over revenue growth does not reflect any potential additional acquisitions, nor does it reflect any meaningful benefit from our expected increase in marketing spend.” Digital Brands expects continued growth through acquisitions and to continue to acquire companies this year and next. Though much smaller than other apparel brands, DBGI just might have the most upside potential. The stock is trading at the low end of it’s range and with so much growth potential if the company hits or exceeds guidance the high end of it’s range could be in the rear-view mirror. The holidays and the seasonal surge in apparel are fast approaching. This seems like the perfect time to celebrate, have fun, and position portfolios with apparel stocks.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.